Recordati
REC.MI
Performance
About Recordati
Recordati is a global pharmaceutical company headquartered in Milan, Italy, developing and commercialising medicines to treat common diseases as well as rare diseases across roughly 150 countries. With a workforce of over 4,450 employees, the company emphasizes life-enhancing and life-changing medicines and is publicly listed on the Italian stock exchange. The Group also operates in chemicals and industrial operations as part of its integrated business activities, and maintains a strong focus on sustainability and governance. Their operations span research, development, manufacturing, and commercialisation through a diversified portfolio and international presence.
Recent News
GBL Joins CVC in €10.7bn Takeover Bid for Recordati
CVC Seeks Partners to Back 10.9 Billion-Euro Italian Drugmaker Recordati Deal: Sources
EQT Joins Bidding Race for Royal Challengers Bengaluru
CVC and GBL Launch €10.73 Billion Offer to Take Recordati Private
STRM.BIO Raises $8M in Series Seed 2 Financing
Tender Offer for Recordati; Sobi's Gout Drug Passes Phase 3 Test
CVC and GBL Unveil €10.7 Bn Take‑Private Offer for Recordati
Moderna's Q1 Revenues Rocket, Thanks to Ex-US Sales
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M
Moderna Licenses Phase 3 Asset to Recordati; ProMIS' Private Placement